Rheumatoid Arthritis Models
- Services
- Autoimmune Diseases
- Rheumatoid Arthritis Models
Rheumatoid Arthritis Models
Rheumatoid arthritis is a chronic autoimmune disorder characterized by persistent joint inflammation, leading to pain, swelling, and potential joint destruction. To facilitate the study of RA pathogenesis and the development of therapeutic interventions, we offers several well-established mouse models:
Model
CIA (Collagen-Induced Arthritis)
Strain
DBA
Induction
Type II collagen + CFA
Immune Response
Adaptive immunity (T & B cells, autoantibodies)
Key Features
Gradual, symmetrical polyarthritis; cartilage & bone erosion
Applications
Standard model for studying RA pathogenesis, testing DMARDs and biologics
Model
CAIA (Collagen Antibody-Induced Arthritis)
Strain
BALB/c
Induction
Anti-CII antibodies + LPS
Immune Response
Innate immunity (complement, neutrophils)
Key Features
Rapid onset; edema and joint destruction without prior sensitization
Applications
Fast evaluation of anti-inflammatory agents; studies on effector mechanisms
Model
AIA in Humanized Mice
Strain
huHSC-NCG-M
Induction
Adjuvant injection
Immune Response
Human immune cells (T cells, cytokines, macrophages)
Key Features
Systemic inflammation; human-like RA phenotype
Applications
Human-specific therapeutic evaluation; immunotherapy and cytokine studies
For more information:
Adjuvant-induced Arthritis (AIA) using HuHSC-NCG-M Humanized Mice
The Adjuvant-Induced Arthritis (AIA) model in HuHSC-NCG-M humanized mice is developed by administering Complete Freund’s Adjuvant (CFA) to induce systemic and joint-specific inflammation in mice. This model mimics human rheumatoid arthritis by activating human immune cells within a murine host, leading to joint swelling, synovial inflammation, and cartilage erosion.
Key Features:
- Utilizes humanized mice with functional human T cells, B cells, and monocytes
- Induces robust joint inflammation, resembling human RA pathology
- Reflects both innate and adaptive human immune responses
- Suitable for evaluating human-specific therapeutics such as monoclonal antibodies, cytokine inhibitors, and cell therapies
- Enables investigation of human immune pathways, cytokine networks, and biomarker discovery in RA
Adalimumab significantly alleviated the claw swelling, while tocilizumab exhibited no obvious efficacy.
Axiocell Biotech Sdn Bhd.
Suite 2-5, Level 18, Plaza Azalea 10, Persiaran Bandaraya, Seksyen 14, 40000 Shah Alam, Selangor.
© 2025 AXIOCELL BIOTECH. All rights reserved.
Developed by Infinicore – Design by LeMoon